#biopharmaceutical
Related Stories (2)
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
September 28, 2026US FDA approves Axsome's drug for Alzheimer's-related agitation - Reuters
US FDA approves Axsome's drug for Alzheimer's-related agitation Reuters
April 30, 2026Related Pages (2)
Untitled
window.wiz_progress&&window.wiz_progress();window.wiz_tick&&window.wiz_tick('lW1Lhc');(function(){'use strict';var c=window,d=[];c.aft_counter=d;var e=[],f=0;function _recordIsAboveFold(a){if(!c._isLa
news.google.com•September 28, 2026
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl) for the Treatment of Agitation Associated with Dementia due to Alzheimer’s Disease
April 30, 2026 14:06 ET | Source: Axsome Therapeutics, Inc. Axsome Therap
globenewswire.com•May 1, 2026